As of June 30, 2026, intangible assets, net, consisted of the following (dollars in thousands):


	Useful Life (Years)	Gross June 30, 2026		Accumulated Amortization			Net June 30, 2026
Indefinite-lived assets:
Trademarks and licenses	N/A	$	5,950	$	—		$	5,950
Amortized intangible assets:
Network relationships	10–21		225,717		(131,562	)		94,155
Member relationships	7–14		196,577		(67,152	)		129,425
Other (1)	3–20		40,310		(26,528	)		13,782
		$	468,554	$	(225,242	)	$	243,312

(1)

Other consists of management contracts, a patient management platform, trade name/trademarks, and developed technology.

As of December 31, 2025, intangible assets, net, consisted of the following (dollars in thousands):


	Useful Life (Years)	Gross December 31, 2025		Accumulated Amortization			Net December 31, 2025
Indefinite-lived assets:
Trademarks and licenses	N/A	$	5,950	$	—		$	5,950
Amortized intangible assets:
Network relationships	10–21		225,717		(125,359	)		100,358
Member relationships	7–14		196,577		(47,908	)		148,669
Other (1)	3–20		40,310		(24,319	)		15,991
		$	468,554	$	(197,586	)	$	270,968

(1)

Other consists of management contracts, a patient management platform, trade name/trademarks, and developed technology.

For the three months ended June 30, 2026 and 2025, the Company recognized amortization expense of $13.8 million and $6.2 million, respectively, in depreciation and amortization in the accompanying condensed consolidated statements of income. For the six months ended June 30, 2026 and 2025, the Company recognized amortization expense of $27.7 million and $12.4 million, respectively, in depreciation and amortization in the accompanying condensed consolidated statements of income. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three and six months ended June 30, 2026 and 2025.